comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists linked to lower risk for death, adverse CV GLP-1s It's important to study the
Description
The only difference is FDA approval indication: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for weight loss
More than 9000 patients were included with follow up of 3.8 years
Injection site reactions are more common with amylin analogs, and the dual-mechanism approach means managing two sets of potential adverse effects
The demand is fueled by compelling demographic shifts
These effects were blunted in CNS-specific GIPR knockout mice, suggesting a key role of CNS GIPR in the control of energy metabolism (138) ( Figure 1 Section C)
